What is the purpose of this new credit facility?

While the filing doesn't explicitly state the precise use, such credit facilities are typically used for general corporate purposes, including working capital, strategic investments, acquisitions, and refinancing existing debt. The substantial amount suggests it's intended to support McKesson's ongoing operational and strategic initiatives.

What are the key maturities for these new loans?

The new credit facilities include a $750.0 million Term Loan A-1 facility due in 2031, a $250.0 million Term Loan A-2 facility due in 2028, and a $1.0 billion revolving credit facility that also matures in April 2031. This provides a staggered maturity profile for the company's debt.

How is the interest rate determined for these facilities?

For the Term Loan A facilities, interest rates are based on either the Adjusted Term SOFR Rate or the Base Rate, plus an applicable margin. For the Revolving Credit Facility, the initial rates are similar, but future rates and commitment fees will fluctuate based on the Company's Total Net Leverage Ratios and public corporate credit ratings, providing a variable cost of capital tied to financial performance and market standing.

What assets are being used as collateral for these loans?

The credit agreement is secured by a security interest in substantially all tangible and intangible assets of the borrower (McKesson Medical-Surgical Top Holdings, Inc.) and certain material U.S. subsidiaries of McKesson Corporation, subject to certain exceptions.

MCK 8-K: Material Agreements & Financial Events

01—Abstract

Summary

Summary of the 8-K filed April 6, 2026. Cited figures are marked; the original filing is the authoritative source.

McKesson Corporation (MCK) announced a significant financing event through an 8-K filing on April 6, 2026.

The Company's subsidiary, McKesson Medical-Surgical Top Holdings, Inc., entered into a new Senior Secured Credit Facilities agreement on April 1, 2026. This agreement provides substantial liquidity, comprising a $750.0 million^a Term Loan A-1 facility due in 2031 and a $250.0 million Term Loan A-2 facility due in 2028, totaling $1.0 billion in term loans.

Additionally, a $1.0 billion^b senior secured revolving credit facility, maturing in April 2031, offers further financial flexibility. This new credit facility, secured by substantially all assets of the borrower and certain subsidiaries, will be used by the Company to manage its ongoing operational and strategic needs.

02—Key points

Key Highlights

McKesson's subsidiary entered into a new Senior Secured Credit Facilities agreement on April 1, 2026.
The new facilities provide up to $1.0 billion in senior secured term loans (Term Loan A-1 and A-2) and a $1.0 billion senior secured revolving credit facility.
The Term Loan A-1 facility matures in 2031, while the Term Loan A-2 facility matures in 2028.
The Revolving Credit Facility matures on April 1, 2031, offering medium-term liquidity.
Interest rates on the term loans are based on Adjusted Term SOFR or Base Rate plus applicable margins (initially 1.250% and 0.250%, respectively).
The revolving credit facility's interest rates and commitment fees vary based on leverage ratios and corporate credit ratings.
Obligations under the Credit Agreement are secured by substantially all tangible and intangible assets of the borrower and certain material U.S. subsidiaries.

03—Questions

Frequently Asked Questions

What is the purpose of this new credit facility?
While the filing doesn't explicitly state the precise use, such credit facilities are typically used for general corporate purposes, including working capital, strategic investments, acquisitions, and refinancing existing debt. The substantial amount suggests it's intended to support McKesson's ongoing operational and strategic initiatives.
What are the key maturities for these new loans?
The new credit facilities include a $750.0 million Term Loan A-1 facility due in 2031, a $250.0 million Term Loan A-2 facility due in 2028, and a $1.0 billion revolving credit facility that also matures in April 2031. This provides a staggered maturity profile for the company's debt.
How is the interest rate determined for these facilities?
For the Term Loan A facilities, interest rates are based on either the Adjusted Term SOFR Rate or the Base Rate, plus an applicable margin. For the Revolving Credit Facility, the initial rates are similar, but future rates and commitment fees will fluctuate based on the Company's Total Net Leverage Ratios and public corporate credit ratings, providing a variable cost of capital tied to financial performance and market standing.
What assets are being used as collateral for these loans?
The credit agreement is secured by a security interest in substantially all tangible and intangible assets of the borrower (McKesson Medical-Surgical Top Holdings, Inc.) and certain material U.S. subsidiaries of McKesson Corporation, subject to certain exceptions.

04—Continue

← View all 8-K filings